These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

721 related items for PubMed ID: 15741547

  • 1. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD.
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [Abstract] [Full Text] [Related]

  • 2. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A.
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [Abstract] [Full Text] [Related]

  • 3. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, Juarez M, Taranto NJ.
    Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
    [Abstract] [Full Text] [Related]

  • 4. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T.
    Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
    [Abstract] [Full Text] [Related]

  • 6. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
    Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C.
    Pathol Biol (Paris); 1997 Jun; 45(6):496-9. PubMed ID: 9309267
    [Abstract] [Full Text] [Related]

  • 7. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
    Teva A, Porrozzi R, Oliveira-Neto MP, Grimaldi GJ.
    J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
    [Abstract] [Full Text] [Related]

  • 8. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB, Mendonça SC, Callahan H, Portal AC, Max G.
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [Abstract] [Full Text] [Related]

  • 9. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S, Marr JJ.
    N Engl J Med; 1992 Mar 12; 326(11):741-4. PubMed ID: 1738379
    [Abstract] [Full Text] [Related]

  • 10. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R, Handjani F, Nouhpisheh MK.
    J Dermatolog Treat; 2001 Sep 12; 12(3):159-62. PubMed ID: 12243707
    [Abstract] [Full Text] [Related]

  • 11. [N-methyl glucamine antimoniate or Glucantime].
    Rapp C, Simon F, Dordain ML.
    Med Trop (Mars); 2000 Sep 12; 60(4):342-3. PubMed ID: 11436584
    [No Abstract] [Full Text] [Related]

  • 12. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
    Friedrich K, Vieira FA, Porrozzi R, Marchevsky RS, Miekeley N, Grimaldi G, Paumgartten FJ.
    J Toxicol Environ Health A; 2012 Sep 12; 75(2):63-75. PubMed ID: 22129235
    [Abstract] [Full Text] [Related]

  • 13. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.
    Soto J, Toledo J, Vega J, Berman J.
    Am J Trop Med Hyg; 2005 Apr 12; 72(4):421-2. PubMed ID: 15827279
    [Abstract] [Full Text] [Related]

  • 14. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi EA, Heshmatkhah A.
    Int J Dermatol; 2012 Oct 12; 51(10):1221-5. PubMed ID: 22994669
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
    Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T.
    Am J Trop Med Hyg; 2009 Feb 12; 80(2):172-5. PubMed ID: 19190206
    [Abstract] [Full Text] [Related]

  • 16. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI, Baptista C, Rubin EF, Vasconcellos Ede C, Lyra MR, Salgueiro Mde M, Saheki MN, Rosalino CM, Madeira Mde F, Silva AF, Confort EM, Schubach Ade O.
    Rev Soc Bras Med Trop; 2011 Feb 12; 44(2):254-6. PubMed ID: 21552747
    [Abstract] [Full Text] [Related]

  • 17. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B, Abbaszadeh B, Khamesipour A.
    Eur J Dermatol; 2005 Feb 12; 15(2):85-7. PubMed ID: 15757817
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G.
    Clin Infect Dis; 2005 May 15; 40(10):1395-403. PubMed ID: 15844060
    [Abstract] [Full Text] [Related]

  • 19. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec 15; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 20. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
    Neves DB, Caldas ED, Sampaio RN.
    Trop Med Int Health; 2009 Dec 15; 14(12):1515-22. PubMed ID: 19954451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.